LEO Pharma

New General Manager appointed to lead LEO Pharma across the Nordic region


Klaus Abel arrives to take the regional helm of the global medical dermatology leader

April 30, Malmo, Sweden: LEO Pharma, a global leader in medical dermatology, has appointed Klaus Abel to take the helm as Managing Director for the Nordics.

Klaus Abel moves into the new role from Lundbeck where he was for 19 years. While at Lundbeck, he held senior roles in Global Marketing and in Commercial Operations in addition to Managing Director positions in Australia/New Zealand from 2007-2011 and Italy from 2016-2018.  In his new position, Klaus will report to Geraldine Murphy, Regional Vice President Cluster North Europe, Australia & New Zealand, LEO Pharma.

I am delighted to be taking charge of LEO Pharma in the Nordics at this exciting time for the organisation. I was attracted to LEO Pharma by its high ambitions, pioneering approach and clear focus on patients. Being a foundation-owned company LEO Pharma has no shareholders and is committed to reinvesting its profits into R&D. These aspects really stand out to me. I am inspired by the opportunity to improve the quality of life of the many people living with skin conditions by engaging all the stakeholders involved in providing care for people suffering from skin disease ranging from patients, policy makers, and healthcare professionals”, said Klaus Abel, Managing Director, LEO Pharma Nordics.

In terms of his approach to his new role, Klaus Abel added, “The organisation has declared its intent to help 125 million patients by 2025. It is an ambitious goal and I look forward to addressing the challenges ahead in bringing that strategy and vision to fruition. I intend to help build a best in class organisation and by increasing collaboration, championing cross functional collaboration in a true multi-channel integration to communication.

As Managing Director for the Nordics Organisation Klaus Abel will lead operations in Denmark, Sweden, Norway , Finland and Iceland. He will be responsible for driving LEO Pharma’s Dermatology business, developing talent and ensuring a successful implementation of LEO Pharma’s 2025 strategy. Klaus will also be part of the Cluster Europe North Australia New Zealand Leadership team.

Geraldine Murphy added, “It is a real pleasure to welcome Klaus Abel to LEO Pharma and the Cluster Leadership team. We very much look forward to working with him going forward to achieve our 2025 goals. We have a fantastic opportunity to draw on Klaus’s extensive knowledge and share experiences between our Cluster countries and collaborate closely together to be the preferred dermatology care partner. Our whole team is committed to helping people achieve healthy skin”.


For further information please contact the Communications team:

Julie Wong, Head of Communications, LEO Pharma UK

T: +44 (0)7825918989 E: comms@leo-pharma.com


About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million. For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com

LEO Pharma Nordics is headquartered in Malmo, Sweden and comprises 55 people conducting commercial operations across both Dermatology and Thrombosis. The team spans Norway, Denmark, Sweden, Finland and Iceland and also has offices in Helsinki and Oslo.

For more information on careers within LEO Pharma Nordics please contact Lars Skouboe, Senior People Partner, E: LQUDK@leo-pharma.com

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate15.4.2020 07:45:16 CESTPress release

BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.

LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma2.3.2020 12:05:26 CETPress release

Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 MEUR has been completed. The initial agreement with Karo Pharma was announced on December 23, 2019 and approved by relevant competition authorities on February 20, 2020. This divestment marks an important step for LEO Pharma towards strategically aligning its portfolio and increasing focus on innovation and dermatology. The divested products include four anti-hemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology products, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®).

With topline growth of 7% in 2019, margin improvements and pipeline success, LEO Pharma paves the way for an ambitious future27.2.2020 21:00:00 CETPress release

LEO Pharma helped 92 million patients and reached revenue of DKK 10,805 million in 2019 - 2019 revenue up by 4% to DKK 10,805 million – with a strong fourth quarter demonstrating further momentum. This was driven by strong performances of Enstilar®, Kyntheum® and the prescription portfolio acquired from Bayer. - Underlying revenue grew by 7%. This excludes currency effects, divestments of non-core business to Karo Pharma and other one-time effects. - Revenue in region Europe+ grew 5% to DKK 6,840 million, due to Enstilar®, Kyntheum® and the acquired Bayer portfolio. - Sales in region International grew 12% to DKK 3,117 million, due to the acquired Bayer portfolio. - US sales declined 22% to DKK 848 million, due to generic competition and price pressure. We continue to see the US as a key growth driver in the future and are stepping up the launch preparations for tralokinumab accordingly. Established business remains the backbone with continued growth and improved profitability - Toplin

LEO Pharma Signs Agreement to Divest Emollients and Proctology Portfolio to Karo Pharma23.12.2019 12:10:00 CETPress release

Ballerup, DENMARK, December 23, 2019 – Today, LEO Pharma announced the sale of 10 products to Karo Pharma AB for 90 MEUR. The divested portfolio isnon-core to LEO Pharma’s business, and was part of the portfolio acquired from Bayer in July 2019. “This divestment is an important step for LEO Pharma towards strategically aligning our portfolio and increasing focus on innovation and dermatology. This well-established portfolio will be better served by Karo Pharma and its team,” said Anders Kronborg, Chief Financial Officer, LEO Pharma. The product portfolio includes four anti-haemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®). Karo Pharma is a fast-growing specialty pharma company that develops and markets products to physicians, pharmacies and directly to healthcare providers. The company is listed on the Swedish stock exchange, Nasdaq Stock

LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD11.12.2019 08:05:00 CETPress release

BALLERUP, Denmark, December 11, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo. IL-13 is a key driver of the type 2 inflammation that plays a major role in AD,(1) which is the most common inflammatory skin disease in the developed world,(2) affecting up to five percent of adults across the United States, Canada, Europe and Japan.(3) AD can have a significant, negative impact on patients’ well-being, primarily due to distressing itch, sleep deprivation and social stigmatization due to visible lesions.(4) “In its moderate-to-severe form, AD can cause unbearable

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom